$17.27−0.82 (−4.53%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Relay Therapeutics (RLAY) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
1 figure withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 40% below its peak, net margin −1800.6%. Worth your attention in FY25: Share count (+80.4%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲53.4%
15.4
FY21→FY25CAGR +50.1%/yr
Net income ($M)▲18.1%
−276.5
FY21→FY25CAGR —
Free cash flow ($M)▲6.1%
−235.9
FY21→FY25CAGR —
Diluted EPS▲31.8%
−1.61
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+80.4%
95.1mn → 171.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$410.0K
−79.7% YoY in FY25 · 2.7% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-1801¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 100.0% → 100.0%. Net margin -1800.6% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7829, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 10,349.0 | 15,355.0 | 10,007.0 | 25,546.0 | 1,381.0 | 3,029.0 | ▲53.4% | +50.1% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 10,349.0 | 15,355.0 | 10,007.0 | 25,546.0 | 1,381.0 | 3,029.0 | ▲53.4% | +50.1% |
Research & development | 279,599.0 | 261,383.0 | 319,089.0 | 330,018.0 | 246,355.0 | 295,650.0 | ▼18.1% | −3.0% |
Selling, general & admin | 51,084.0 | 56,710.0 | 76,592.0 | 74,950.0 | 65,978.0 | 57,386.0 | ▼26.0% | −0.3% |
Total operating expenses | 330,683.0 | 318,093.0 | 382,475.0 | 398,546.0 | 300,656.0 | 367,727.0 | ▼16.8% | −3.6% |
Operating incomefeeds ROC rank | −320,290.0 | −302,738.0 | −372,468.0 | −373,000.0 | −299,275.0 | −364,698.0 | ▲18.7% | — |
Other income, net | 26,701.0 | 26,259.0 | 34,760.0 | 31,027.0 | 8,766.0 | 826.0 | — | — |
Pretax income | −293,589.0 | −276,479.0 | −337,708.0 | −341,973.0 | −290,509.0 | −363,872.0 | ▲18.1% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −293,633.0 | −276,479.0 | −337,708.0 | −341,973.0 | −290,509.0 | −363,872.0 | ▲18.1% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.50 | −1.61 | −2.36 | −2.79 | −2.59 | −3.82 | ▲31.8% | — |
Diluted shares (mn) | 219.16 | 171.59 | 142.87 | 122.58 | 112.23 | 95.14 | ▲20.1% | +15.9% |
| Margins | ||||||||
Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ▲0.0pp | +0.0pp |
Operating margin | −3094.9% | −1971.6% | −3722.1% | −1460.1% | −21670.9% | −12040.2% | ▲1750.5pp | +10068.6pp |
Net margin | −2837.3% | −1800.6% | −3374.7% | −1338.7% | −21036.1% | −12012.9% | ▲1574.1pp | +10212.4pp |
† TTM = trailing four quarters through 2026-09-30.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Relay Therapeutics' revenue last fiscal year?
Relay Therapeutics reported revenue of $15.4M in fiscal 2025, up 53.4% from fiscal 2024.
What was Relay Therapeutics' net income?
Relay Therapeutics reported net income of −$276.5M in fiscal 2025, a net margin of −1800.6%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

